410 related articles for article (PubMed ID: 18645343)
1. Pharmacologic management of isolated low high-density lipoprotein syndrome.
Bermúdez V; Cano R; Cano C; Bermúdez F; Arraiz N; Acosta L; Finol F; Pabón MR; Amell A; Reyna N; Hidalgo J; Kendall P; Manuel V; Hernández R
Am J Ther; 2008; 15(4):377-88. PubMed ID: 18645343
[TBL] [Abstract][Full Text] [Related]
2. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Jones PH
Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
[TBL] [Abstract][Full Text] [Related]
4. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
5. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.
Toth PP
Am J Cardiol; 2005 Nov; 96(9A):50K-58K; discussion 34K-35K. PubMed ID: 16291015
[TBL] [Abstract][Full Text] [Related]
6. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
7. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
Brown BG; Zhao XQ
Am J Cardiol; 2008 Apr; 101(8A):58B-62B. PubMed ID: 18375243
[TBL] [Abstract][Full Text] [Related]
8. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
[TBL] [Abstract][Full Text] [Related]
9. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.
Rosenson RS
Curr Probl Cardiol; 2005 May; 30(5):241-79. PubMed ID: 15829899
[TBL] [Abstract][Full Text] [Related]
10. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
Barter PJ; Kastelein JJ
J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
[TBL] [Abstract][Full Text] [Related]
11. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
12. The treatment of dyslipidemia--what's left in the pipeline?
Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
[TBL] [Abstract][Full Text] [Related]
13. Low HDL-C: a secondary target of dyslipidemia therapy.
Rosenson RS
Am J Med; 2005 Oct; 118(10):1067-77. PubMed ID: 16194634
[TBL] [Abstract][Full Text] [Related]
14. Lifetime risk for developing dyslipidemia: the Framingham Offspring Study.
Cobain MR; Pencina MJ; D'Agostino RB; Vasan RS
Am J Med; 2007 Jul; 120(7):623-30. PubMed ID: 17602937
[TBL] [Abstract][Full Text] [Related]
15. High-density lipoprotein cholesterol: current perspective for clinicians.
Whayne TF
Angiology; 2009; 60(5):644-9. PubMed ID: 19240106
[TBL] [Abstract][Full Text] [Related]
16. HDL-c is a powerful lipid predictor of cardiovascular diseases.
Bruckert E; Hansel B
Int J Clin Pract; 2007 Nov; 61(11):1905-13. PubMed ID: 17655681
[TBL] [Abstract][Full Text] [Related]
17. High-density lipoproteins and cardiovascular disease: 2010 update.
Alwaili K; Awan Z; Alshahrani A; Genest J
Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):413-23. PubMed ID: 20222819
[TBL] [Abstract][Full Text] [Related]
18. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
19. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?
Rizzo M; Berneis K; Carmina E; Rini GB
Am J Obstet Gynecol; 2008 Jan; 198(1):28.e1-5. PubMed ID: 18166299
[TBL] [Abstract][Full Text] [Related]
20. Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study.
Srinivasan SR; Frontini MG; Xu J; Berenson GS
Pediatrics; 2006 Jul; 118(1):201-6. PubMed ID: 16818566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
